You are here

  • Home
  • Archive
  • Volume 77, Issue Suppl 2
  • FRI0398 Sl-401, a novel targeted therapy directed to the interleukin-3 receptor (CD123), kills plasmacytoid dendritic cells from systemic sclerosispatients

Citation Tools

Article menu

Download PDFPDF

FRIDAY, 15 JUNE 2018
Systemic sclerosis, myositis and related syndromes – etiology, pathogenesis and animal models
FRI0398 Sl-401, a novel targeted therapy directed to the interleukin-3 receptor (CD123), kills plasmacytoid dendritic cells from systemic sclerosispatients
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Ah Kioon M, Lindsay R, Chen J, et al
FRI0398 Sl-401, a novel targeted therapy directed to the interleukin-3 receptor (CD123), kills plasmacytoid dendritic cells from systemic sclerosispatients
Annals of the Rheumatic Diseases 2018;77:731-732.